# US 2021/0060149 A1 · Compounds including a mutant kras sequence and a lipid and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0060149 A1
- Document ID: US20210060149A1
- Status: Published application
- Kind: A1
- Application number: 16/977,155
- Filed: 2019-03-01
- Published: 2021-03-04
- Earliest claimed: 2018-03-02
- Assignees: Elicio Therapeutics, Inc.
- Applicants: Elicio Therapeutics Inc.
- Inventors: Peter C. DEMUTH; Julian ADAMS; Martin STEINBUCK
- Web page: https://patentgrep.com/patent/US20210060149A1

## CPC

- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 47/543: {Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}
- A61K 39/001164: {GTPases, e.g. Ras or Rho}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/544: {Phospholipids}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 35/00: Antineoplastic agents
- C07K 14/82: Translation products from oncogenes
- C12N 9/14: Hydrolases (3)
- C12N 9/96: Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C12Y 306/05002: Small monomeric GTPase (3.6.5.2)
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The invention features a compound including a mutant KRAS sequence and a lipid, where the mutant KRAS sequence is conjugated to the lipid by a linker, and (i) the linker includes one or more polyethylene glycol blocks, (ii) the lipid is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), and (iii) the mutant KRAS sequence comprises or consists of the amino acid sequence selected from the group consisting of SEQ ID NOs:1-7 and 22-30. The invention features a composition including one or more compounds of the invention and a pharmaceutically acceptable carrier. The invention also features a method of treating a cancer in a human patient, the method including administering the composition to the patient. Further, the invention features a kit comprising the compound.

## Claims

### Claim 1

A compound comprising a mutant KRAS sequence and a lipid, wherein the mutant KRAS sequence is conjugated to the lipid by a linker, and (i) the linker comprises one or more polyethylene glycol blocks, (ii) the lipid is 1,2-distearoyi-sa-glycero-3-ohosphoethanolarnine (DSPE), and (iii) the mutant KRAS sequence consists of an amino acid sequence selected from the group consisting of CYKLVVVGADGVGKSALTI (SEQ ID NO:1), CYKLVVVGAVGVGKSALTI (SEQ ID NO:2), CYKLVVVGARGVGKSALTI (SEQ ID NO:3), CYKLVVVGAAGVGKSALTI (SEQ ID NO:4), CYKLVVVGASGVGKSALTI (SEQ ID NO:5), CYKLVVVGACGVGKSALTI (SEQ ID NO:6), CYKLVVVGATGVGKSALTI (SEQ ID NO:22), and CYKLVVVGAGDVGKSALTI (SEQ ID NO:7),

### Claim 2 (depends on 1)

The compound of claim 1, wherein the mutant KRAS sequence consists of an amino acid sequence selected from the group consisting of YKLVVVGADGVGKSALTI (SEQ ID NO:23), YKLVVVGAVGVGKSALTI (SEQ ID NO:24), YKLVVVGARGVGKSALTI (SEQ ID NO:25), YKLVVVGAAGVGKSALTI (SEQ ID NO:26), YKLVVVGASGVGKSALTI (SEQ ID NO:27), YKLVVVGACGVGKSALTI (SEQ ID NO:28), YKLVVVGATGVGKSALTI (SEC) ID NO:29), and YKLVVVGAGDVGKSALTI (SEQ ID NO:30).

### Claim 3 (depends on 1, 2)

The compound of claim 1 or 2, wherein the mutant KRAS sequence, at its N-terminus, is conjugated to the linker through a cysteine-maleimide linkage.

### Claim 4 (depends on 1, 2)

The compound of claim 1 or 2, wherein linker comprises 48 repeat units of polyethylene glycol.

### Claim 5 (depends on 1, 2)

The compound of claim 1 or 2, wherein the mutant KRAS sequence, at its N-terminus, is conjugated to the following structure:

### Claim 6 (depends on 1, 2)

A composition comprising one or more compounds of claim 1 or 2, and a pharmaceutically acceptable carrier.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the composition comprises (1) a compound comprising the amino add sequence YKLVVVGADGVOKSALTI (SEQ ID NO:23), (2) a compound comprising the amino add sequence YKLVVVGAVGVGKSALTI (SEQ ID NO:24), (3) a compound comprising the amino acid sequence YKLVVVGARGVGKSALTI (SEQ ID NO:25), (4) a compound comprising the amino add sequence YKLVVVGAAGVGKSALTI (SEQ ID NO:26), (5) a compound comprising the amino acid sequence YKLVVVGASGVGKSALTI (SEQ ID NO:27), (6) a compound comprising the amino acid sequence YKLVVVGACGVGKSALTI (SEQ ID NO:28) or a compound comprising the amino acid sequence YKLVVVGATGVGKSALTI (SEQ ID NO:29), and (7) a compound comprising the amino acid sequence YKLVVVGAGDVGKSALTI (SEQ ID NO:30).

### Claim 8 (depends on 6)

The composition of claim 6, wherein the composition comprises (1) a compound comprising the amino acid sequence CYKLVVVGADGVGKSALTI (SEQ ID NO:1), (2) a compound comprising the amino acid sequence CYKLVVVGAVGVGKSALTI (SEQ ID NO:2), (3) a compound comprising the amino acid sequence GYKLVVVGARGVGKSALTI (SEQ ID NO:3), (4) a compound comprising the amino acid sequence CYKLVVVGAAGVGKSALTI (SEQ ID NO:4), (5) a compound comprising the amino acid sequence CYKLVVVGASGVGKSALTI (SEQ ID NO:5), (6) a compound comprising the amino acid sequence GYKLVVVGACGVGKSALTI (SEQ ID NO:6) or a compound comprising the amino acid sequence CYKLVVVGATGVGKSALTI (SEQ ID NO:22), and (7) a compound comprising the amino acid sequence GYKLVVVGAGDVGKSALTI (SEQ ID NO:7).

### Claim 9 (depends on 6)

The composition of claim 6, wherein the composition further comprises a compound consisting of the nucleotide sequence 5′-TCGTCGTTTTGTCGTTTTGTCGTT-3′ (SEQ ID NO:8), which, at its 5′ end, is bonded or linked by a linker to the following lipid:
or a salt thereof,
wherein X is O or S.

### Claim 10 (depends on 6)

The composition of claim 6, wherein the composition comprises 700 μg of each compound.

### Claim 11 (depends on 9)

The composition of claim 9, wherein the nucleotide sequence is bonded to the lipid.

### Claim 12 (depends on 6)

A method of treating a cancer in a human patient, the method comprising administering the composition of claim 6 the patient.

### Claim 13 (depends on 12)

The method of claim 12, wherein the method further comprises administering an adjuvant.

### Claim 14 (depends on 13)

The method of claim 13, wherein the adjuvant comprises a CpG nucleotide sequence.

### Claim 15 (depends on 14)

The method of claim 14, wherein the CpG nucleotide sequence comprises 5′-TCGTCGTTTTGTCGTTTTGTCGTT-3′ (SEQ ID NO: 8).

### Claim 16 (depends on 12)

The method of claim 12, wherein 0.1 mg, 0.5 mg, or 2.5 mg of the adjuvant is administered.

### Claim 17 (depends on 12)

The method of claim 12, wherein the method further comprises administering to the patient a compound consisting of the nucleotide sequence 5′-TCGTCGTTTTGTCGTTTTGTCGTT-3′ (SEQ ID NO:8), which, at its 5′ end, is bonded or linked by a linker to the following lipid:
or a salt thereof,
wherein X is O or S.

### Claim 18 (depends on 17)

The method of claim 17, wherein the nucleotide sequence is bonded to the lipid.

### Claim 19 (depends on 17)

The method of claim 17, wherein 0.1 mg, 0.5 mg, or 2.5 mg of the compound consisting of the nucleotide sequence 5′-TCGTCGTTTTGTCGTTTTGTCGTT-3′ (SEQ ID NO:8), which, at its 5′ end, is bonded or linked by a linker to the following lipid:
or a salt thereof,
wherein X is O or S,
is administered.

### Claim 20 (depends on 12)

The method of claim 12, wherein the cancer is a pancreatic cancer, a lung cancer, or a colorectal cancer.

### Claim 21 (depends on 12)

The method of claim 12, wherein all internucleoside groups connecting the nucleosides in 5′-TCGTCGTTTTGTCGTTTTGTCGTT-3′ (SEQ ID NO:8) are phosphorothioates.

### Claim 22 (depends on 1, 2)

A kit comprising (i) a compound of claim 1 or 2, and (ii) a compound consisting of the nucleotide sequence 5′-TCGTCGTTTTGTCGTTTTGTCGTT-3′ (SEQ ID NO:8), which, at its 5′ end, is bonded or linked by a linker to the following lipid:
or a salt thereof,
wherein X is O or S.
